Adefovir Dipivoxil 10 mgClinical Pharmacokinetics

• Oral bioavailability 59%, T1/2 ? 7 hours

• Pharmacokinetics not affected by food, chronic hepatitis B disease, demographic characteristics

• No clinically relevant drug-drug interactions

  • Not substrate or inhibitor of CYP450
  • Lamivudine, acetaminophen, ibuprofen, trimethoprim/sulfamethoxazole

• Change in dosing interval required in patients with moderate to severe renal impairment

  • Increased exposure with CLcr < 50 mL/min

• No dose alteration for hepatic impairment

Previous slide

Next slide

Back to first slide

View graphic version